Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Novel Treatment for Syndromic Ichthyoses

This study has been withdrawn prior to enrollment.
(Study was withdrawn due to lack of eligible population for study)
Information provided by (Responsible Party):
Amy Paller, Northwestern University Identifier:
First received: April 22, 2010
Last updated: May 15, 2015
Last verified: May 2015
This is an open label-pilot study to assess the efficacy and safety of a novel cholesterol-lovastatin topical solution in children with rare syndromic ichthyoses. Often times, these children have difficulty in finding easily applied treatments to make their psoriasiform and ichthyotic plaques more manageable. We propose the use of a cholesterol-lovastatin topical solution as a treatment option with the hypothesis that it will lead to regression of involved areas and decreased erythema and warty-like appearance of the plaques. We plan to enroll children with syndromic ichthyoses over the age of 1 year for a 12 month study with a total of 5 visits and 5 phone calls.

Condition Intervention Phase
Syndromic Ichthyoses
CHILD Syndrome
Smith Lemli Opitz Syndrome
Conradi Syndrome
Drug: Lovastatin
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses

Resource links provided by NLM:

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Physician global assessment of severity (PGAS) [ Time Frame: 12 months ]
    Difference in physician global assessment of severity at baseline compared to month 12

Secondary Outcome Measures:
  • Total body surface area (TBSA) [ Time Frame: 12 months ]
    Percent change in TBSA affected at baseline compared to at month 12

Enrollment: 0
Study Start Date: July 2011
Arms Assigned Interventions
Experimental: Lovastatin solution
All patients will receive lovastatin solution
Drug: Lovastatin
Topical lovastatin applied to red, rashy areas two times daily for 12 months


Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed Consent form signed by the subject or subject's legal representative; also, if the subject is under the age of majority but capable of providing assent, signed assent from the subject.
  • Diagnosis of a syndromic ichthyoses (verified by Dr Amy S. Paller).
  • Children and adults 12 months of age and above

Exclusion Criteria:

  • Use of any investigational drug within the 30 days before enrollment.
  • Current malignancy.
  • Pregnancy or breastfeeding during the study. (All female subjects of childbearing potential will be assessed for pregnancy at all visits.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01110642

Sponsors and Collaborators
Northwestern University
Principal Investigator: Amy S Paller, MD Northwestern University
  More Information

Responsible Party: Amy Paller, Professor and Chair of Department of Dermatology, Professor of Pediatrics, Northwestern University Identifier: NCT01110642     History of Changes
Other Study ID Numbers: 2010-04-15
Study First Received: April 22, 2010
Last Updated: May 15, 2015

Additional relevant MeSH terms:
Ichthyosiform Erythroderma, Congenital
Ichthyosis, Lamellar
Smith-Lemli-Opitz Syndrome
Pathologic Processes
Skin Abnormalities
Congenital Abnormalities
Infant, Newborn, Diseases
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Abnormalities, Multiple
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Steroid Metabolism, Inborn Errors
Lipid Metabolism Disorders
Metabolic Diseases
L 647318
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors processed this record on April 26, 2017